$ARCC

Ares Capital (ARCC) Raised $750M Through 2033 Notes. Should Dividend Fans Care?

Ares Capital (ARCC) raised $750M via 6.250% notes maturing in 2033, paying down bank borrowings. Q2 earnings covered dividends, but net income and NAV per share declined. Short interest is high, and loan quality slightly worsened. The move extends liquidity but reflects a slower deal environment.

Original reporting
Published Sep 21, 2026, 5:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 5:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ares Capital (ARCC) Raised $750M Through 2033 Notes. Should Dividend Fans Care? — source image
Decision brief

The 30-second read

$ARCCNeutralMed
01

Why it matters

The $750M note issuance extends debt maturity to 2033, providing liquidity but at a higher cost than prior issues, affecting credit metrics and dividend sustainability.

02

Market read

New senior note issuance is a material corporate action for ARCC, influencing its credit profile and dividend outlook.

03

What to watch

Potential future credit tightening could make the longer‑dated notes a liability if asset quality deteriorates.

Relevance 8/10Novelty 8/10Timing: post-issuance (after September 15 note closing)

Background

Ares Capital (ARCC) is a business development company that regularly issues debt to fund its portfolio and dividend.

Company-level read

Ticker impact

$ARCCNeutralMedium confidence
Context

Ares Capital priced $750M of 6.25% unsecured notes maturing 2033, using proceeds to refinance bank borrowings.

Expected impact

Potential modest upside if investors view the longer runway as credit strength; downside risk if higher coupon is seen as cost increase.

Evidence & confidence

The raise is sizable for a BDC, but the coupon is above prior issues, creating a mixed signal for valuation.

Market effects

May influence other BDCs as investors compare financing costs and dividend sustainability.

Limited to U.S. BDC and credit markets.

Low global impact; primarily a domestic corporate financing event.

Counterpoint

Higher coupon could signal rising funding costs for the sector, suggesting caution on ARCC.

Key entities

  • Ares Capital

    Business development company issuing new senior notes.

  • Scott Lem

    Chief Financial Officer who commented on liquidity.

Related articles

$SHELMed

Shell Wins Canadian Reserves Disclosure Exemption — Twenty-Two Years After the Scandal That Shook Investor Confidence

Shell received exemptive relief from Canadian regulators to use its American reporting framework for oil and gas disclosures, following its $16.5B acquisition of ARC Resources. The exemption applies to specific Canadian reporting requirements, with conditions to file relevant disclosures in Canada. Shell's 2004 reserves scandal involved overstating 4.47B barrels of oil equivalent.

$ARCCMed

Ares Leads $2.2 Billion Healthcare Loan

Ares Management Corp. is leading a $2.2 billion loan to MedImpact Holding Inc. to finance its acquisition of Medical Card System, Inc. The second-lien loan may pay at least 8% over the baseline rate. Ares manages $671 billion in assets and recently reported $708 billion in non-accruing loans. MedImpact serves 20 million customers and processes $40 billion in pharmacy transactions annually.

$ARCCMed

Ares Capital Q2 Earnings Call Highlights

Management expects industry credit conditions to continue normalizing toward longer-term averages, though it said performance differences among managers have widened. Schnabel said Ares Capital added four investments to non-accrual during the quarter, but the companies were in unrelated businesses and did not indicate a sector-specific trend.